ACE Report Cover
TKA: No effect of fibrin sealant on reducing blood loss and functional recovery
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
ARTHROPLASTY
TKA: No effect of fibrin sealant on reducing blood loss and functional recovery .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2013;1(8):6 Acta Orthop. 2013 Apr;84(2):153-8. doi: 10.3109/17453674.2013.769082. Epub 2013 Jan 25

24 patients (48 knees) undergoing simultaneous bilateral total knee arthroplasty (TKA) had their knees 1:1 randomized to receive an intraoperative application of either fibrin sealant or saline. The purpose was to determine the adjuvant effect of fibrin sealant on postoperative blood loss in patients already treated with preoperative tranexamic acid and tourniquet use. Blood loss was calculated 24 hours following surgery, and patients were assessed for functional recovery up to 21 days postoperatively. The findings indicated that there was no decrease in blood loss in knees treated with fibrin sealant, and that pain, swelling, range of motion, and isokinetic strength was similar between knees, regardless of the application of fibrin sealant or saline.


Detalles de la financiación de la publicación +
Financiación:
Industry funded
Patrocinador:
Johnson and Johnson Medical Ltd.
Conflicts:
None disclosed

Riesgo de sesgo

8,5/10

Criterios de información

17/20

Índice de fragilidad

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sí = 1

Incierto = 0,5

No relevante = 0

No = 0

La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.

4/4

Randomization

3/4

Outcome Measurements

2/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.

¿Por qué se necesitaba ahora este estudio?

Postoperative blood loss following total knee arthroplasty (TKA) may be associated with significant morbidity and impaired functional recovery. There have been many developments in stemming blood loss following surgery, one of which is a topical application of fibrin sealant. While the hemostatic agent has been investigated in prior studies, there is limited evidence of its effect as an adjunct to other blood loss regimens (ie. tranexamic acid, intramedullary femoral canal plugging), as well as its effect on functional recovery.

¿Cuál era la pregunta principal de la investigación?

What is the effect of adjuvant fibrin sealant on postoperative blood loss and early functional recovery following total knee arthroplasty, with blood loss measured within the first 24 postoperative hours and function assessed up to 21 days postoperatively?

Características del estudio +
Population:
24 patients (n=48 knees) undergoing simultaneous bilateral total knee arthroplasty. All patients were given preoperative cefuroxime (1.5g intravenously) and tranexamic acid (0.5g 10 min prior to tourniquet inflation (100mmHg above systolic pressure) on the first knee, followed by 0.5g after deflation and before inflation on the second knee), and were operated on with a medial parapatellar approach. Closure of the femoral canal was achieved with an autologous bone plug, and one intra-articular drain (passive) was installed in each knee. Patients either received AGC or Vanguard ROCC (Biomet) prostheses. (Mean age: 65 years)
Intervention:
Fibrin sealant group: After implantation of the knee prosthesis, and while the tourniquet was still inflated, 10mL of fibrin sealant (Evicel) was sprayed onto all instrumented cut surfaces and soft tissues. (n=24 knees)
Comparison:
Control group: After implantation of the knee prosthesis, and while the tourniquet was still inflated, 10mL of saline was sprayed onto all instrumented cut surfaces and soft tissues. (n=24 knees)
Outcomes:
Primary outcome was blood loss within the first 24h postoperatively, measured by drain output. Secondary outcomes included pain on a visual analog scale (VAS), knee swelling measured by knee circumference (1cm proximal to patella), knee range of motion (ROM) using a goniometer, and isometric knee strength.
Methods:
RCT, Double-blind, Placebo-controlled, Single-centre
Time:
Blood loss was measured at 24h postoperatively. Knee pain and swelling were assessed daily until postoperative day (POD) 3, then again at POD 7 and 21. ROM and strength assessment was conducted at POD 3, 7, and 21.
¿Cuáles fueron los hallazgos importantes?
  • Mean blood loss calculated from drains at 24h postoperatively was 582mL (SD 328mL) for knees allocated to the fibrin sealant and 576mL (SD 289mL) in knees treated with saline (p=0.9).
  • There was no significant difference in pain between groups either at rest or during flexion at any time-point (all p>0.05).
  • Knee swelling did not significantly differ between groups at any assessment (p>0.05).
  • ROM assessment of both flexion and extension were observed to be similar between groups at each time point, with no significant differences being observed (all P>0.05).
  • Isometric knee strength was similarly reduced from baseline at day 3 assessment in both groups, with gradual recovery. Recovery by day 21 was still lower that preoperative values. There were no significant differences between groups at any of the assessments (all P>0.05).
¿Qué es lo que más debo recordar?

The use of the fibrin sealant, Evicel, in total knee arthroplasty did not reduce blood loss, nor promote any benefit in functional recovery when compared to placebo treatment with saline in the contralateral knee.

¿Cómo afectará esto al cuidado de mis pacientes?

The results of the present study do not support the application of adjuvant fibrin sealant as a means to stem postoperative blood loss following total knee arthroplasty. However, there was concern that hyperemia caused by the deflation of the tourniquet may have flushed out the fibrin sealant prior to eliciting any potential effect. It may be worthwhile to determine if there is an effect of Evicel in the absence of tourniquet use.

DESCARGO DE RESPONSABILIDAD

El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.

0 de 4 artículos mensuales GRATIS desbloqueados
Ha alcanzado su límite de vistas de 4 artículos gratuitos este mes

Acceda a OrtoEvidencia por tan sólo 1,99 $ a la semana.

Manténgase conectado con las últimas pruebas. Cancele en cualquier momento.
  • Valoraciones críticas de los últimos ensayos controlados aleatorizados de gran impacto y revisiones sistemáticas en ortopedia
  • Acceso al contenido del podcast OrthoEvidence, que incluye colaboraciones con el Journal of Bone and Joint Surgery, entrevistas con cirujanos reconocidos internacionalmente y mesas redondas sobre noticias y temas ortopédicos
  • Suscripción a The Pulse, un boletín quincenal basado en la evidencia y diseñado para ayudarle a tomar mejores decisiones clínicas
Upgrade
Bienvenido
¿Ha olvidado su contraseña?
Comience hoy mismo su prueba GRATUITA

Su cuenta estará afiliada a
e incluye acceso gratuito a OrthoEvidence


O
¿Olvidó su contraseña?

O
Compruebe su correo electrónico

Si existe una cuenta con la dirección de correo electrónico proporcionada, se le enviará un correo electrónico para restablecer la contraseña. Si no ve el correo electrónico, compruebe su carpeta de correo no deseado o spam.

Si necesita más ayuda póngase en contacto con nuestro equipo de asistencia.

Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Traducir Informe ACE

OrthoEvidence utiliza un servicio de traducción de terceros para que el contenido sea accesible en varios idiomas. Tenga en cuenta que, aunque se hace todo lo posible para garantizar la exactitud, las traducciones no siempre son perfectas.

Cómo citar esto ACE Report

OrthoEvidence. TKA: No effect of fibrin sealant on reducing blood loss and functional recovery. OE Journal. 2013;1(8):6. Available from: https://myorthoevidence.com/AceReport/Show/tka-no-effect-of-fibrin-sealant-on-reducing-blood-loss-and-functional-recovery

Copiar cita
Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Función de miembro Premium

Para acceder a esta función, debe iniciar sesión en una cuenta Premium de OrthoEvidence.

Compartir ACE Report